Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 3

Antiplatelet drugs in cardiological practice: Established strategies and new developments

Authors Florian Krötz, Hae-Young Sohn, Volker Klauss

Published Date June 2008 Volume 2008:4(3) Pages 637—645

DOI http://dx.doi.org/10.2147/VHRM.S2691

Published 30 June 2008

Florian Krötz, Hae-Young Sohn, Volker Klauss

Cardiology, Medical Policlinic, Ludwig-Maximilians-Universität, Ziemssenstr. 1, 80336 München

Abstract: A common pathophysiological course in vascular diseases is an overwhelming activation and aggregation of blood platelets, which results in atherothrombosis. By causing the last decisive step of cerebral, coronary, or peripheral arterial ischemia thrombotic complications of atherosclerotic disease represent a major player in death cause statistics of most western countries. The development of novel therapies against platelet-dependent thrombosis and the concurrent improvement of existing therapeutic strategies thus is a paramount focus of pharmaceutical research. Currently, efficiency, dosing and indications of established antiplatelet substances are being re-evaluated, whilst new, so far unrecognized molecular targets for inhibition of platelet activity come up front. This not only allows for interesting new therapeutical options, but also widens our insight into the role platelets play in atherosclerosis in general. This article summarizes the relevant pathophysiology of platelet activation, presents current concepts in antiplatelet drug therapy, and highlights the role of platelets in vascular diseases apart from atherothrombosis.

Keywords: atherothrombosis, antiplatelet drug therapy, pathophysiology, platelet activation

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Synthesis, characterization, and evaluation of paclitaxel loaded in six-arm star-shaped poly(lactic-co-glycolic acid)

Chen Y, Yang Z, Liu C, Wang C, Zhao S, Yang J, Sun H, Zhang Z, Kong D, Song C

International Journal of Nanomedicine 2013, 8:4315-4326

Published Date: 7 November 2013

Reduced prefrontal cortex activation using the Trail Making Test in schizophrenia

Fujiki R, Morita K, Sato M, Kamada Y, Kato Y, Inoue M, Shoji Y, Uchimura N

Neuropsychiatric Disease and Treatment 2013, 9:675-685

Published Date: 16 May 2013

Distracted pedestrian sustains orbital fracture while on cell phone

Edell AR, Jung JJ, Solomon JM, Palu RN

Clinical Ophthalmology 2013, 7:671-673

Published Date: 3 April 2013

Anti-αvβ3 antibody guided three-step pretargeting approach using magnetoliposomes for molecular magnetic resonance imaging of breast cancer angiogenesis

Yan C, Wu Y, Feng J, Chen W, Liu X, Hao P, Yang R, Zhang J, Lin B, Xu Y, Liu R

International Journal of Nanomedicine 2013, 8:245-255

Published Date: 11 January 2013

Multidisciplinary treatment for peripheral arterial occlusive disease and the role of eHealth and mHealth

Fokkenrood HJP, Lauret GJ, Scheltinga MRM, Spreeuwenberg C, de Bie RA, Teijink JAW

Journal of Multidisciplinary Healthcare 2012, 5:257-263

Published Date: 8 October 2012

Effect of molecular weight of polyethyleneimine on loading of CpG oligodeoxynucleotides onto flake-shell silica nanoparticles for enhanced TLR9-mediated induction of interferon-α

Manoharan Y, Ji Q, Yamazaki T, Chinnathambi S, Chen S, Ganesan S, Hill JP, Ariga K, Hanagata N

International Journal of Nanomedicine 2012, 7:3625-3635

Published Date: 16 July 2012

Screening for type 2 diabetes in a multiethnic setting using known risk factors to identify those at high risk: a cross-sectional study

Laura J Gray, Jennifer R Tringham, Melanie J Davies, et al

Vascular Health and Risk Management 2010, 6:837-842

Published Date: 20 September 2010

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia

Odd Erik Johansen, Pål Johan Vanberg, Bente Kvarv Kilhovd, Anders Palmstrøm Jørgensen

Vascular Health and Risk Management 2009, 5:121-128

Published Date: 18 December 2008